AstralBio

AstralBio is a synthetic biology company focused on developing next-generation genomic medicines. Founded in 2024 by Vikram Sudarsan and Patrick Hsu, the company leverages a proprietary platform to design and engineer novel RNA-based therapies and gene-editing tools. AstralBio aims to address challenging diseases by integrating high-throughput screening with computational biology to optimize drug candidates. The company emerged from stealth with a 225 million Series A funding round led by prominent life science investors. Its mission is to expand the reach of programmable medicines across a variety of therapeutic areas, including oncology and rare diseases. By utilizing advanced technologies like bridge recombinases, AstralBio seeks to overcome current limitations in genetic medicine delivery and precision.